Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) gets into your bloodstream within hours of your first injection, reaching a stable concentration in your system after roughly four to five weeks of weekly dosing. That said, most people don't feel anything meaningful in week one — and that's completely normal. These are prescription-only medicines assessed individually by a clinician before treatment begins, so how quickly you notice any effect will depend on your starting dose, your body, and how your prescriber titrates your treatment over time.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture it: it's a Tuesday morning, pen in the fridge door, first dose done. You feel nothing unusual. That's not a sign something went wrong. Semaglutide is absorbed gradually through the subcutaneous tissue and enters general circulation over the following hours, reaching its peak blood concentration somewhere between 24 and 72 hours after injection, according to the NHS semaglutide medicines page. By about day three you have the highest single-dose concentration you'll see at 0.25mg, but a single dose at the starting level isn't designed to produce a strong appetite effect. The 0.25mg starting dose exists specifically to let your digestive system adapt, not to produce immediate results.
The key concept is steady state. Because semaglutide has a half-life of approximately seven days, each weekly injection adds to what's still circulating from the last one. After four or five consecutive weekly doses, the amount entering your system each week roughly equals the amount leaving, and that's when your body is actually running on a stable, therapeutic level of the medicine. For most people that point arrives around weeks four to five on 0.25mg, just as a prescriber would typically be considering whether to move to the next dose.
If you want to understand how semaglutide's behaviour in the body compares across injection and tablet forms, the full semaglutide pharmacokinetics guide covers both in detail.
The titration schedule (starting at 0.25mg and stepping up, roughly every four weeks, through 0.5mg, 1.0mg, 1.7mg and eventually 2.4mg) isn't arbitrary bureaucracy. It maps directly onto how the medicine accumulates. At each new dose, your body spends another four to five weeks reaching a new steady state at that higher level. Appetite suppression and the slowing of gastric emptying both intensify as semaglutide concentrations rise, which is why many people notice a meaningful difference in hunger around weeks eight to twelve rather than in the first fortnight.
Some people do feel nausea or a mild reduction in appetite in the first week or two, particularly after moving up a dose step. That's the GI-led side-effect profile that comes with GLP-1 receptor agonists: nausea, occasional loose stools, a sense of fullness arriving faster at meals. These effects are often most noticeable in the 24–72 hours after an injection (coinciding with that peak concentration window) and they tend to ease as your body adjusts. They're not a signal to stop; they're often a signal the medicine is working as expected.
The timeline for when Wegovy actually starts working on weight has its own nuances, and it's worth reading alongside this page if your main concern is when you'll see the scales move rather than when the medicine is technically active.
Because semaglutide's half-life is roughly seven days, it doesn't disappear quickly after a missed dose or after stopping treatment. After one missed injection, meaningful concentrations are still circulating. If you're curious about the full clearance picture, the page on how long Wegovy is in your system explains exactly how the seven-day half-life plays out from first dose through to full clearance.
This has practical implications. If you're having elective surgery, your prescribing team needs to know you're on Wegovy; NHS England's guidance on weight-management injections specifically advises informing your anaesthetist because of the slowed gastric emptying. If you're planning to conceive, the lingering presence of the medicine in your system is why a wash-out period is recommended before trying. And if your appetite returns after stopping, that's pharmacologically expected, not a personal failure.
For a closer look at the exit timeline specifically, the page on how long Wegovy stays in your system goes through the half-life maths and what it means in practice.
Wegovy injections can be given on any day of the week, but choosing a consistent day helps both adherence and steady-state stability. The injection site (abdomen, thigh or upper arm) doesn't meaningfully change how quickly the medicine is absorbed, though rotating sites reduces local reactions. Storage matters more than people expect: Wegovy pens are refrigerated at 2–8°C; always check the patient information leaflet for the exact room-temperature window if you need to take the pen somewhere with you.
Questions about cost and what a private prescription through a regulated pharmacy actually involves are covered on the Wegovy cost in the UK page, worth a read if you're weighing up your options before committing to treatment. And for a broader picture of what Wegovy is and who it's licensed for, the Wegovy treatment overview covers eligibility, results evidence and the full dose pathway in one place.
If you're ready to find out whether Wegovy is clinically appropriate for you, our prescribers review consultations the same day. Start your free consultation and a GPhC-registered clinician will assess your situation and guide you from there.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.